ARRY-520 (Filanesib) is a synthetic kinesin spindle protein (KSP) inhibitor (IC50: 6 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 121 | |
10 mg | In stock | $ 217 | |
20 mg | In stock | $ 320 | |
50 mg | In stock | $ 717 | |
100 mg | In stock | $ 1147 |
Description | ARRY-520 (Filanesib) is a synthetic kinesin spindle protein (KSP) inhibitor (IC50: 6 nM). |
Targets&IC50 | KSP:6 nM |
In vitro | ARRY-520 retains activity in multidrug-resistant cell lines. The EC50s of ARRY-520 for inhibition of proliferation of HCT-15, NCI/ADR-RES and K562/ADR cells are 3.7, 14 and 4.2 nM respectively. ARRY-520 (10 nM) blocks a majority of cells in mitosis with the monopolar spindle structure typical of KSP inhibition . ARRY-520 (10 nM) induces mitotic arrest as judged by both increased phosphorylation of histone H3 and the accumulation of cyclin B1 in four cells . ARRY-520 and Paclitaxel exhibit the same cytotoxic effect on Type I and II cells. The GI50 at 48 h for Type II EOC cells is 0.0015 μM for ARRY-520. For Type I EOC cells, the GI50 at 48 h is > 3 μM for ARRY-520. ARRY-520 (1 nM) induces a significant G2M cell cycle block in OCI-AML3 cells at 24 hours . |
In vivo | ARRY-520 (10, 15, 20, 30 mg/kg, i.p.) is active in UISO-BCA-1 xenograft, and also superior to paclitaxel in mice bearing subcutaneous HT-29, HCT-116, MDA-MB-231 and A2780 xenografts. ARRY-520 is superior to docetaxel in the androgen receptor-negative prostate cancer xenograft model PC-3 . RPMI 8226 tumor xenografts are particularly sensitive to low doses of ARRY-520 (12.5 mg/kg, i.p.) . ARRY-520 significantly inhibits tumor growth in HL60 and MV4-11 xenografts of SCID mice at concentrations of 27 mg/kg and 20 mg/kg, respectively . |
Synonyms | ARRY 520 |
CAS No. | 885060-09-3 |
Chemical Formula | C20H22F2N4O2S |
Molecular Weight | 420.48 |
Solubility | DMSO: 95 mg/mL (225.93 mM) |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom